| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(01)06964-1 |
| P8608 | Fatcat ID | release_inqg6xlqevcdzdredho45atadm |
| P698 | PubMed publication ID | 11747939 |
| P50 | author | Ronald N Jones | Q120908182 |
| Daniel J. Diekema | Q43292463 | ||
| P2860 | cites work | The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria | Q24519053 |
| Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721 | Q24676621 | ||
| Oxazolidinones, a new class of synthetic antituberculosis agent in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis | Q28325680 | ||
| Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis | Q28346136 | ||
| Oxazolidinones: a review | Q28373208 | ||
| In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents | Q28379204 | ||
| Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). | Q30453672 | ||
| Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group | Q31797996 | ||
| Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study | Q31918107 | ||
| Efficacy of linezolid in a staphylococcal endocarditis rabbit model | Q32061964 | ||
| Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid | Q33942509 | ||
| Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine | Q43613495 | ||
| Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group | Q43613993 | ||
| Linezolid breakpoints | Q43650735 | ||
| Linezolid resistance in a clinical isolate of Staphylococcus aureus | Q43690311 | ||
| Susceptibility testing with linezolid by different methods, in relation to published 'general breakpoints'. | Q43726465 | ||
| Successful treatment of disseminated Mycobacterium chelonae infection with linezolid | Q43732842 | ||
| Emergence of vancomycin resistance in coagulase-negative staphylococci | Q44441075 | ||
| Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort | Q44918473 | ||
| Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin | Q45206563 | ||
| Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors | Q45722453 | ||
| Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias. | Q54043070 | ||
| Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin). | Q54062867 | ||
| Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. | Q54066894 | ||
| Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (linezolid): new treatment options for infections due to resistant organisms. | Q54075012 | ||
| Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci | Q74468119 | ||
| In vitro antibiotic synergy against Flavobacterium meningosepticum: implications for therapeutic options | Q74578381 | ||
| Vancomycin-resistant enterococci | Q74578393 | ||
| A novel antimicrobial agent joins the battle against resistant bacteria | Q74587568 | ||
| Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program | Q77496292 | ||
| In vitro activity of linezolid and eperezolid against anaerobic bacteria | Q77664314 | ||
| In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to the novel oxazolidinones eperezolid (PNU-100592) and linezolid (PNU-100766) | Q78093828 | ||
| In vitro activity of linezolid and eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria | Q80057159 | ||
| In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci | Q33977497 | ||
| In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains | Q33979251 | ||
| MICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animals | Q33979553 | ||
| Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci | Q33979988 | ||
| Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections | Q33981016 | ||
| Activities of linezolid against rapidly growing mycobacteria | Q33981613 | ||
| Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus | Q33982746 | ||
| Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid | Q34052631 | ||
| Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature | Q34312876 | ||
| Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. | Q35122591 | ||
| In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones | Q35123200 | ||
| In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. | Q35123415 | ||
| In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. | Q35125132 | ||
| In vitro activities in new oxazolidinone antimicrobial agents against enterococci | Q35125827 | ||
| In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis | Q35128574 | ||
| In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species | Q35132865 | ||
| In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. | Q35133106 | ||
| Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions | Q35138447 | ||
| In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium | Q35139128 | ||
| Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis | Q35318121 | ||
| Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group | Q36688995 | ||
| Daptomycin disrupts membrane potential in growing Staphylococcus aureus | Q36756893 | ||
| Efficacy of linezolid in experimental otitis media | Q39473141 | ||
| In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori | Q39474501 | ||
| In vitro activities of linezolid against multiple Nocardia species | Q39477004 | ||
| Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil | Q39478313 | ||
| Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay | Q39557542 | ||
| The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin | Q39785029 | ||
| Bacteremia due to viridans streptococci in neutropenic patients: a review | Q40707109 | ||
| Oxazolidinones: new antibacterial agents | Q41478614 | ||
| New approaches to reduce Staphylococcus aureus nosocomial infection rates: treating S. aureus nasal carriage | Q41707274 | ||
| Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds | Q42214936 | ||
| In-vitro activity of oxazolidinones against Mycobacterium avium Complex | Q42276718 | ||
| Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity | Q42557282 | ||
| Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial | Q43546278 | ||
| Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid | Q43588787 | ||
| P433 | issue | 9297 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibiotic | Q12187 |
| P304 | page(s) | 1975-1982 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Oxazolidinone antibiotics | |
| P478 | volume | 358 |
| Q90929349 | A genetics-free method for high-throughput discovery of cryptic microbial metabolites |
| Q34563237 | A guide to antibiotics for the interventional radiologist |
| Q41881947 | A substrate radical intermediate in catalysis by the antibiotic resistance protein Cfr. |
| Q24681027 | Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program |
| Q39895301 | Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype |
| Q33185287 | Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997-2000. |
| Q28075453 | Alternative pre-approved and novel therapies for the treatment of anthrax |
| Q46013312 | An expedient stereoselective and chemoselective synthesis of bicyclic oxazolidinones from quinols and isocyanates. |
| Q36233502 | Anti-MRSA agents: under investigation, in the exploratory phase and clinically available |
| Q36283731 | Antibiotic resistance in Staphylococcus aureus and its relevance in therapy |
| Q35627661 | Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis |
| Q34156349 | Antibiotics and bacterial resistance in the 21st century |
| Q27025271 | Antibiotics that target protein synthesis |
| Q41919747 | Antimicrobial activity of allylic thiocyanates derived from the Morita-Baylis-Hillman reaction |
| Q42846946 | Aqueous and Vitreous Penetration of Linezolid and Levofloxacin After Oral Administration |
| Q56969305 | Catalytic Oxidative Carbonylation of Amino Moieties to Ureas, Oxamides, 2-Oxazolidinones, and Benzoxazolones |
| Q43595562 | Catalytic synthesis of hydroxymethyl-2-oxazolidinones from glycerol or glycerol carbonate and urea |
| Q47611899 | Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones |
| Q46548640 | Clinical experience with linezolid for the treatment of central nervous system infections |
| Q44285699 | Clinical experience with linezolid for the treatment of nocardia infection |
| Q26750683 | Combating Tuberculosis Infection: A Forbidding Challenge |
| Q40067743 | Current therapies for the treatment of multidrug-resistant tuberculosis in children in India |
| Q48951110 | Decoding the cryptic genomes of fungi: the promise of novel antibiotics |
| Q44306333 | Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone |
| Q59296697 | Direct Assembly of 2-Oxazolidinones by Chemical Fixation of Carbon Dioxide |
| Q53739563 | Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis. |
| Q38777085 | Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones |
| Q26766204 | Drug-Induced Metabolic Acidosis |
| Q35683967 | Drug-resistant tuberculosis: emerging treatment options |
| Q36172366 | Effect of linezolid on the 50% lethal dose and 50% protective dose in treatment of infections by Gram-negative pathogens in naive and immunosuppressed mice and on the efficacy of ciprofloxacin in an acute murine model of septicemia |
| Q35826505 | Effect of oral linezolid on the pressor response to intravenous tyramine |
| Q44895305 | Effects of protein-calorie malnutrition on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats |
| Q87624258 | Efficacy and safety of linezolid for the treatment of infections in children: a meta-analysis |
| Q33412664 | Efficacy and safety of linezolid in treating gram-positive bacterial infection in the elderly: a retrospective study |
| Q33412202 | Efficacy of linezolid on gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia. |
| Q37875564 | Eight-year (2002-2009) summary of the linezolid (Zyvox® Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries |
| Q34756483 | Emerging resistance to antibiotics against respiratory bacteria: impact on therapy of community-acquired pneumonia in children |
| Q44516868 | Failure of intravenous linezolid to treat Clostridium difficile associated diarrhea |
| Q36702968 | First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States |
| Q37757660 | Global tuberculosis drug development pipeline: the need and the reality. |
| Q24542412 | Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients |
| Q44572563 | High-performance liquid chromatographic analysis of DA-7867, a new oxazolidinone, in human plasma and urine and in rat tissue homogenates |
| Q43251091 | Improved antimicrobial activity of linezolid against vancomycin-intermediate Staphylococcus aureus |
| Q50855186 | In Vitro Activities of LCB 01-0648, a Novel Oxazolidinone, against Gram-Positive Bacteria. |
| Q49552573 | In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus |
| Q42112190 | In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea |
| Q40410703 | In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria |
| Q35006670 | In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci |
| Q42123065 | In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods |
| Q44084920 | In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method |
| Q39792579 | In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria |
| Q30227297 | Intervention strategies for an influenza pandemic taking into account secondary bacterial infections |
| Q38053000 | Is repositioning of drugs a viable alternative in the treatment of tuberculosis? |
| Q35139437 | LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States |
| Q36730155 | Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014). |
| Q37663491 | Linezolid compared with vancomycin for the prevention of methicillin-resistant Staphylococcus aureus or Staphylococcus epidermidis vascular graft infection in rats: A randomized, controlled, experimental study |
| Q38175628 | Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations. |
| Q38929509 | Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index |
| Q43130393 | Linezolid penetration into cerebrospinal fluid and brain tissue |
| Q44479766 | Linezolid-induced anemia |
| Q57057570 | Linezolid-induced pure red cell aplasia: a case report and literature review |
| Q36724345 | Linezolid: a new antibiotic for newborns and children? |
| Q39044932 | Linezolid: a promising option in the treatment of Gram-positives. |
| Q47577709 | Long-lasting successful dissemination of resistance to oxazolidinones in MDR Staphylococcus epidermidis clinical isolates in a tertiary care hospital in France |
| Q37071990 | Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr |
| Q37072346 | Multidrug- and extensively drug-resistant tuberculosis, Germany |
| Q92325220 | Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs |
| Q35673808 | New developments in antibacterial choice for lower respiratory tract infections in elderly patients |
| Q37996998 | New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future |
| Q36237707 | Nosocomial bacterial infections in Intensive Care Units. I: Organisms and mechanisms of antibiotic resistance |
| Q35073345 | Novel antibacterial agents for the treatment of serious Gram-positive infections |
| Q44455151 | Occurrence of MRSA endocarditis during linezolid treatment |
| Q35637071 | Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria |
| Q40565401 | Oxazolidinones and glycopeptides |
| Q64218681 | Palladium-Catalyzed Carboxy-Alkynylation of Propargylic Amines Using Carbonate Salts as Carbon Dioxide Source |
| Q46845906 | Pharmacoeconomic evaluation of linezolid versus teicoplanin in bacteremia by Gram-positive microorganisms |
| Q35785222 | Pharmacogenomic strategies against resistance development in microbial infections |
| Q58854622 | Pharmacokinetics of DA-7218, a new oxazolidinone, and its active metabolite, DA-7157, after intravenous and oral administration of DA-7218 and DA-7157 to rats |
| Q35546926 | Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: intestinal first-pass effect |
| Q64080142 | Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies |
| Q34837338 | Quorum sensing: an emerging target for antibacterial chemotherapy? |
| Q64131294 | Recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos grampositivos en el paciente crítico |
| Q38353565 | Safety and tolerability profile of second-line anti-tuberculosis medications |
| Q37736231 | Selective in vivo and in vitro activities of 3,3'-4-nitrobenzylidene-bis-4-hydroxycoumarin against methicillin-resistant Staphylococcus aureus by inhibition of DNA polymerase III. |
| Q35215457 | Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. |
| Q83079095 | Spread of cfr gene among staphylococci conferring resistance to linezolid in a patient under treatment |
| Q42795664 | Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program |
| Q36894458 | Staphylococci. |
| Q44859922 | Successful medical treatment of multiple brain abscesses due to Nocardia farcinica in a paediatric renal transplant recipient. |
| Q44877259 | Successful treatment of disseminated cerebritis complicating methicillin-resistant Staphylococcus aureus Endocarditis unresponsive to vancomycin therapy with linezolid. |
| Q36933217 | Surgical site infection prophylaxis strategies for cardiothoracic surgery: a decision-analytic model |
| Q64942397 | Synthesis and Biological Evaluation of Pyrimidine-oxazolidin-2-arylimino Hybrid Molecules as Antibacterial Agents. |
| Q44239645 | Synthesis and antibacterial activity of 5-substituted oxazolidinones |
| Q37268425 | Synthesis and antibacterial activity of novel curcumin derivatives containing heterocyclic moiety |
| Q46381177 | Synthesis of some heterofunctionalized penicillanic acid derivatives and investigation of their biological activities |
| Q80362477 | The Advantage of Bactericidal Drugs in the Treatment of Infection |
| Q44437069 | Tooth discoloration after treatment with linezolid |
| Q36758570 | Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions |
| Q36688930 | Use of linezolid in children: an overview of recent advances |
| Q41655310 | Validation of a commercial dry-form broth microdilution device (Sensititre) for testing tedizolid, a new oxazolidinone |
| Q42285540 | ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries |
Search more.